{"success":true,"data":{"pressRelease":{"id":"158747","rtpr_id":"nGNX5NnhzZ-20261001","ticker":"SLDB","exchange":"NASDAQ","all_tickers":["SLDB"],"title":"Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","published_at":"2026-10-01T20:05:00.104Z","article_body":"CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.\n(Nasdaq: SLDB) (the “Company”), a life sciences company developing\nprecision genetic medicines for neuromuscular and cardiac diseases, today\nannounced a grant of 8,150 restricted stock units (“RSUs”) to one newly\nhired employee.\n\nThe RSUs vest in four equal installments on each one-year anniversary of the\ngrant date until the fourth anniversary of the grant date. Vesting of the\nequity awards is subject to the applicable employee’s continued service with\nthe Company through each applicable vesting date.\n\nThis grant was made pursuant to the Company’s 2024 Inducement Stock\nIncentive Plan and was made as an inducement material to the employee’s\nacceptance of employment with the Company in accordance with Nasdaq Listing\nRule 5635(c)(4).\n\nAbout Solid Biosciences\nSolid Biosciences is a precision genetic medicine company focused on advancing\na portfolio of gene therapy candidates targeting rare neuromuscular and\ncardiac diseases, including SGT-003 for Duchenne muscular dystrophy\n(Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for\ncatecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for\nTNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac\ndiseases. The Company is also focused on developing innovative libraries of\ngenetic regulators and other enabling technologies with promising potential to\nsignificantly impact gene therapy delivery cross-industry. Solid is advancing\nits diverse pipeline and delivery platform in the pursuit of uniting experts\nin science, technology, disease management, and care. Patient-focused and\nfounded by those directly impacted by Duchenne, Solid’s mission is to\nimprove the daily lives of patients living with devastating rare diseases. For\nmore information, please visit www.solidbio.com and follow us on LinkedIn at\nSolid Biosciences\n(https://www.globenewswire.com/Tracker?data=y2uscrMEIUaU2KkJCULzzB14PPOaKYEQXiplEBqfxczXk5_oa8eXlBFyyRB9BV1m90FN-7PdScY0qESGWXp96XqAvTDZ8XuzbiUUdREBDwV2FJ0yk4m4zfChE-l_lctq)\nand X at @Solid_Bio.\n\nSolid Biosciences Investor Contact:\nNicole Anderson\nSenior Director, Investor Relations and Corporate Communications\nSolid Biosciences Inc.\ninvestors@solidbio.com\n\nMedia Contact:\nAmir Khan\nCorporate Affairs Practice\nSyneos Health\namir.khan@Syneoshealth.com\n(347) 249-0230\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bb5e6b30-d9d9-464f-8c64-33a09eacc3fb)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5NnhzZ-20261001","title":"Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","ticker":"SLDB","created":"2026-10-01T20:05:00.104Z","tickers":["SLDB"],"exchange":"NASDAQ","article_body":"CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.\n(Nasdaq: SLDB) (the “Company”), a life sciences company developing\nprecision genetic medicines for neuromuscular and cardiac diseases, today\nannounced a grant of 8,150 restricted stock units (“RSUs”) to one newly\nhired employee.\n\nThe RSUs vest in four equal installments on each one-year anniversary of the\ngrant date until the fourth anniversary of the grant date. Vesting of the\nequity awards is subject to the applicable employee’s continued service with\nthe Company through each applicable vesting date.\n\nThis grant was made pursuant to the Company’s 2024 Inducement Stock\nIncentive Plan and was made as an inducement material to the employee’s\nacceptance of employment with the Company in accordance with Nasdaq Listing\nRule 5635(c)(4).\n\nAbout Solid Biosciences\nSolid Biosciences is a precision genetic medicine company focused on advancing\na portfolio of gene therapy candidates targeting rare neuromuscular and\ncardiac diseases, including SGT-003 for Duchenne muscular dystrophy\n(Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for\ncatecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for\nTNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac\ndiseases. The Company is also focused on developing innovative libraries of\ngenetic regulators and other enabling technologies with promising potential to\nsignificantly impact gene therapy delivery cross-industry. Solid is advancing\nits diverse pipeline and delivery platform in the pursuit of uniting experts\nin science, technology, disease management, and care. Patient-focused and\nfounded by those directly impacted by Duchenne, Solid’s mission is to\nimprove the daily lives of patients living with devastating rare diseases. For\nmore information, please visit www.solidbio.com and follow us on LinkedIn at\nSolid Biosciences\n(https://www.globenewswire.com/Tracker?data=y2uscrMEIUaU2KkJCULzzB14PPOaKYEQXiplEBqfxczXk5_oa8eXlBFyyRB9BV1m90FN-7PdScY0qESGWXp96XqAvTDZ8XuzbiUUdREBDwV2FJ0yk4m4zfChE-l_lctq)\nand X at @Solid_Bio.\n\nSolid Biosciences Investor Contact:\nNicole Anderson\nSenior Director, Investor Relations and Corporate Communications\nSolid Biosciences Inc.\ninvestors@solidbio.com\n\nMedia Contact:\nAmir Khan\nCorporate Affairs Practice\nSyneos Health\namir.khan@Syneoshealth.com\n(347) 249-0230\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bb5e6b30-d9d9-464f-8c64-33a09eacc3fb)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-01T20:05:00.15825146Z","server_sent_at_ms":1790885100158},"received_at":"2026-10-01T20:05:00.209Z","source_url":null},"analysis":{"id":"147376","press_release_id":"158747","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Solid Biosciences granted 8,150 restricted stock units to one newly hired employee as an employment inducement.\n\nThe RSUs vest in four equal annual installments and were issued under the 2024 Inducement Stock Incentive Plan per Nasdaq Listing Rule 5635(c)(4).\n\nThis is a routine, de minimis equity grant disclosure with no bearing on the company's clinical pipeline or financials.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine inducement grant -- suppress from feeds."},"keyFigures":{"customDimensions":{"vesting":"four equal annual installments over four years","rsus_granted":8150}},"namedEntities":{"people":[{"name":"Nicole Anderson","role":"Senior Director, Investor Relations and Corporate Communications"}],"products":["SGT-003","SGT-212","SGT-501","SGT-601"],"companies":[{"name":"Solid Biosciences Inc.","ticker":"SLDB","relationship":"filer"},{"name":"Syneos Health","relationship":"media relations agency"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Boilerplate inducement grant of 8,150 RSUs to a single new hire under Nasdaq Rule 5635(c)(4). No financial or operational significance."},"tickerRelevance":{"others":[],"primary":"SLDB"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine-inducement-grant","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Solid Biosciences granted 8,150 restricted stock units to one newly hired employee as an employment inducement.\n\nThe RSUs vest in four equal annual installments and were issued under the 2024 Inducement Stock Incentive Plan per Nasdaq Listing Rule 5635(c)(4).\n\nThis is a routine, de minimis equity grant disclosure with no bearing on the company's clinical pipeline or financials.","key_figures":{"customDimensions":{"vesting":"four equal annual installments over four years","rsus_granted":8150}},"named_entities":{"people":[{"name":"Nicole Anderson","role":"Senior Director, Investor Relations and Corporate Communications"}],"products":["SGT-003","SGT-212","SGT-501","SGT-601"],"companies":[{"name":"Solid Biosciences Inc.","ticker":"SLDB","relationship":"filer"},{"name":"Syneos Health","relationship":"media relations agency"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-01T20:05:04.350Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine-inducement-grant","issuerAuthored":true}},"durationMs":4125,"modelName":"glm-5.3-flashx"}}